Zymeworks Inc. (ZYME) is having quite a Monday, with shares rocketing higher on unusually heavy trading volume of 2.17 million shares compared to its typical 728,750. The reason? Some genuinely impressive cancer trial results that could reshape treatment for a difficult-to-treat cancer.
Zymeworks, along with partners Jazz Pharmaceuticals Inc. (JAZZ) and BeOne Medicines Inc. (ONC), announced topline results from the Phase 3 HERIZON-GEA-01 trial. This study tested Ziihera (zanidatamab-hrii) combined with chemotherapy, with or without BeOne's Tevimbra (tislelizumab), as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma.
That's a mouthful, but here's what matters: both treatment combinations worked remarkably well.
What The Trial Showed
Both Ziihera plus chemotherapy and the triple combination of Ziihera plus Tevimbra and chemotherapy demonstrated highly statistically significant and clinically meaningful improvements in progression-free survival compared to the control arm of trastuzumab plus chemotherapy, which represents the current standard of care.
The triple combination went even further, showing clinically meaningful and statistically significant improvements in overall survival. That's the gold standard endpoint in cancer trials—actual extension of life, not just delaying disease progression.
Ziihera plus chemotherapy alone demonstrated a clinically meaningful effect with a strong trend toward statistical significance in overall survival at this first analysis. The trial continues with an additional planned interim analysis for this combination currently expected in mid-2026.
Particularly encouraging: the benefits with Ziihera plus Tevimbra and chemotherapy were observed in both PD-L1-positive and PD-L1-negative patient subgroups, suggesting broad applicability across different patient populations.
Beyond The Primary Endpoints
Both combinations also showed improvements in key secondary endpoints including objective response rate and duration of response versus the control arm. These supportive findings strengthen the case for the primary efficacy results.
What Happens Next
Jazz Pharmaceuticals plans to submit the data for presentation at a major medical meeting in the first quarter of 2026 and for publication in a peer-reviewed journal. The company also intends to pursue rapid adoption in the National Comprehensive Cancer Network Guidelines, which influence treatment standards across the United States.
On the regulatory front, Jazz expects to submit a supplemental Biologics License Application in the first half of 2026 seeking approval for Ziihera as a first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma, for use as part of a standard chemotherapy regimen with or without Tevimbra.
Zanidatamab is already approved in the United States, Europe, and China for treating second-line biliary tract cancer, marketed under the trade name Ziihera by Jazz and BeOne.
The Financial Angle
For Zymeworks, this represents a significant validation of its drug development platform. The company is eligible for additional regulatory and commercial milestones, plus tiered royalties on net sales of Ziihera from Jazz and BeOne.
Investors responded enthusiastically to the news. ZYME stock surged 36.20% to $25.23, while JAZZ climbed 20.45% to $169.92. Even ONC gained 3.37% to $378.14 in Monday trading.
The market reaction makes sense. Positive Phase 3 data in oncology, particularly with overall survival benefits, dramatically de-risks the regulatory pathway and validates the commercial potential of a therapy that could become a new standard of care.
